Crescita Therapeutics (TSE:CTX) Sets New 52-Week High – Should You Buy?

Crescita Therapeutics Inc. (TSE:CTX)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as C$0.77 and last traded at C$0.77, with a volume of 43000 shares. The stock had previously closed at C$0.76.

Crescita Therapeutics Stock Performance

The stock has a market capitalization of C$13.96 million, a PE ratio of 37.50 and a beta of -1.34. The company has a quick ratio of 2.29, a current ratio of 2.80 and a debt-to-equity ratio of 17.34. The firm has a 50 day moving average price of C$0.73 and a 200-day moving average price of C$0.56.

Crescita Therapeutics (TSE:CTX) last announced its quarterly earnings data on Monday, May 11th. The company reported C($0.06) earnings per share (EPS) for the quarter. Crescita Therapeutics had a negative return on equity of 2.07% and a negative net margin of 1.38%.The firm had revenue of C$5.64 million during the quarter.

About Crescita Therapeutics

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.